ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
In addition, ImmunoGen announced that in connection with the previously announced appointment of Daniel S. Char as ImmunoGen’s Senior Vice President and Chief Legal Officer, the compensation committee of ImmunoGen’s Board of Directors granted to
The Employee Options and the Char Options have an exercise price of
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individuals’ entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Employee Options and the Char Options were granted as such inducement material to the new employees and
ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.